| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P50 | author | Koussay Dellagi | Q95146463 |
| P2093 | author name string | Ali Saad | |
| Hechmi Louzir | |||
| Moez Elloumi | |||
| Kamel Boukef | |||
| Ramzi Jeddi | |||
| Abderrahman Abdelkefi | |||
| Amel Lakhal | |||
| Lamia Torjman | |||
| Saloua Ladeb | |||
| Tarek Ben Othman | |||
| Ahlem Amouri | |||
| Assia Ben Hassen | |||
| Neila Ben Romdhane | |||
| Abdeladhim Ben Abdeladhim | |||
| Habib Ksouri | |||
| Halima El Omri | |||
| Hatem Belaaj | |||
| Mohamed Hsaïri | |||
| Fahmi Msadek | |||
| Lamia Aissaouï | |||
| Tunisian Multiple Myeloma Study Group | |||
| P2860 | cites work | Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 |
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma | Q34401962 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma | Q35848744 | ||
| High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials | Q36714825 | ||
| New drugs for myeloma | Q36865500 | ||
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 | ||
| Diagnosis and management of multiple myeloma | Q43817786 | ||
| Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | Q44101949 | ||
| Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | Q44200289 | ||
| Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | Q44265645 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity | Q44971172 | ||
| Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant | Q45205050 | ||
| First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma | Q46558044 | ||
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
| Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 | ||
| Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? | Q48011772 | ||
| Thalidomide and thrombosis. A meta-analysis. | Q53235157 | ||
| Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study | Q56995088 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma | Q74082581 | ||
| Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study | Q79811602 | ||
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
| Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring | Q80184760 | ||
| Does maintenance therapy with thalidomide benefit patients with multiple myeloma? | Q80395737 | ||
| Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial | Q80776203 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thalidomide | Q203174 |
| multiple myeloma | Q467635 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1805-1810 | |
| P577 | publication date | 2007-09-17 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial | |
| P478 | volume | 111 |
| Q37125283 | A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma |
| Q84496036 | A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma |
| Q45972180 | Abdelkefi A, Ladeb S, Torjman L, Ben Othman T, Lakhal A, Ben Romdhane N, El Omri H, Elloumi M, Belaaj H, Jeddi R, Aissaouï L, Ksouri H, Ben Hassen A, Msadek F, Saad A, Hsaïri M, Boukef K, Amouri A, Louzir H, Dellagi K, Ben Abdeladhim A, on behalf of |
| Q43078127 | Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. |
| Q37289168 | Advances in therapy of multiple myeloma |
| Q81963707 | Autologous transplantation for multiple myeloma |
| Q81752493 | Bibliography. Current world literature. Tolerance induction |
| Q60976678 | Biology, treatment, and time |
| Q35097338 | Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia |
| Q46238706 | Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts |
| Q46094234 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure |
| Q37370051 | Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. |
| Q36301287 | Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion |
| Q37432227 | Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma |
| Q38033590 | Evolving therapeutic paradigms for multiple myeloma: back to the future |
| Q24197999 | First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies |
| Q37575688 | First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective |
| Q37303213 | Front line treatment of elderly multiple myeloma in the era of novel agents |
| Q38148272 | Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials |
| Q37457285 | Frontline treatment in elderly patients with multiple myeloma |
| Q53470095 | High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. |
| Q37867568 | High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma |
| Q37723000 | How best to use new therapies in multiple myeloma |
| Q37653286 | How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. |
| Q60355874 | Immunomodulatory agents in oncology |
| Q53469257 | Impact of early relapse after auto-SCT for multiple myeloma. |
| Q37143728 | Individualizing treatment of patients with myeloma in the era of novel agents. |
| Q44921598 | Induction therapy in multiple myeloma |
| Q37411805 | Initial therapy in multiple myeloma: investigating the new treatment paradigm |
| Q37654409 | Integrating novel therapies in the transplant paradigm |
| Q37507513 | International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation |
| Q37530452 | International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). |
| Q46913027 | Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients? |
| Q42096911 | Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia |
| Q40341372 | Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization |
| Q83425187 | Liquid tumors in the elderly |
| Q93541724 | Maintenance therapy in multiple myeloma |
| Q34973992 | Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials |
| Q43121688 | Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma |
| Q37533983 | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens |
| Q83411634 | Multiple myeloma |
| Q85840509 | Multiple myeloma |
| Q86139784 | Multiple myeloma |
| Q38176293 | Multiple myeloma maintenance therapy: a review of the pharmacologic treatment |
| Q37219747 | Multiple myeloma--an update on diagnosis and treatment. |
| Q37823496 | Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. |
| Q83390194 | New generation pharmacotherapy in elderly multiple myeloma patients |
| Q37661825 | New treatments for myeloma |
| Q46494742 | New treatments in multiple myeloma: beyond optimal treatment |
| Q37688691 | Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents |
| Q33639796 | Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates |
| Q80942743 | One or two autografts for myeloma? |
| Q37274353 | Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma |
| Q37280737 | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). |
| Q90950107 | Prognosis value of RBBP8 expression in plasma cell myeloma |
| Q81918216 | Progress in multiple myeloma |
| Q84606604 | Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis |
| Q42580823 | Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. |
| Q37505952 | Recent trends in the management of newly diagnosed multiple myeloma |
| Q33990944 | Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms |
| Q47771466 | Retracted publications in the drug literature |
| Q37391117 | Role of autologous and allogeneic stem cell transplantation in myeloma |
| Q37300004 | Role of thalidomide in previously untreated patients with multiple myeloma. |
| Q37375819 | Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma |
| Q24610430 | Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance |
| Q39576312 | Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited |
| Q43282882 | Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma |
| Q84595891 | Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis |
| Q36765107 | Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma |
| Q41819684 | Stem cell transplantation for multiple myeloma |
| Q37367737 | Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis |
| Q37075738 | Thalidomide for treatment of multiple myeloma: 10 years later |
| Q34034447 | Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma |
| Q43273410 | Thalidomide maintenance in multiple myeloma: certainties and controversies |
| Q51369301 | Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. |
| Q35932505 | Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. |
| Q46226924 | Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study |
| Q37209935 | The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma |
| Q37457279 | The role of high-dose therapy with autologous stem cell support in the era of novel agents |
| Q43168670 | The role of maintenance therapy in the treatment of multiple myeloma |
| Q37268527 | The role of novel drugs in multiple myeloma |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q34122646 | Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy |
| Q45918038 | Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. |
| Q37328204 | Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). |
| Q37542173 | Treatment of multiple myeloma: a comprehensive review |
| Q43082868 | Treatment of newly diagnosed multiple myeloma |
| Q37324251 | Treatment of newly diagnosed myeloma. |
| Q37819769 | Treatment of patients with multiple myeloma: an overview of systematic reviews |
| Q38469490 | Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic |
| Q84536445 | [Autologous stem cell transplantation in the treatment of multiple myeloma--single center experience] |
Search more.